196 related articles for article (PubMed ID: 23049248)
1. Management of bone metastases in refractory prostate cancer--role of denosumab.
Paller CJ; Carducci MA; Philips GK
Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
[TBL] [Abstract][Full Text] [Related]
2. Bone health and prostate cancer.
Saylor PJ; Smith MR
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):20-7. PubMed ID: 19901958
[TBL] [Abstract][Full Text] [Related]
3. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.
Smith MR
Urol Oncol; 2008; 26(4):420-5. PubMed ID: 18593621
[TBL] [Abstract][Full Text] [Related]
4. New and emerging therapies for bone metastases in genitourinary cancers.
Saylor PJ; Armstrong AJ; Fizazi K; Freedland S; Saad F; Smith MR; Tombal B; Pienta K
Eur Urol; 2013 Feb; 63(2):309-20. PubMed ID: 23201471
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies to prevent skeletal morbidity in men with prostate cancer.
Saylor PJ; Lee RJ; Smith MR
J Clin Oncol; 2011 Sep; 29(27):3705-14. PubMed ID: 21860001
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.
Autio KA; Scher HI; Morris MJ
Curr Treat Options Oncol; 2012 Jun; 13(2):174-88. PubMed ID: 22528368
[TBL] [Abstract][Full Text] [Related]
7. The role of RANK-ligand inhibition in cancer: the story of denosumab.
Castellano D; Sepulveda JM; García-Escobar I; Rodriguez-Antolín A; Sundlöv A; Cortes-Funes H
Oncologist; 2011; 16(2):136-45. PubMed ID: 21285392
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer.
Spencer S; Marini BL; Figg WD
Anticancer Res; 2012 Jul; 32(7):2391-8. PubMed ID: 22753695
[TBL] [Abstract][Full Text] [Related]
9. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
[TBL] [Abstract][Full Text] [Related]
10. Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects.
Fusco V; Di Maio M; Valsecchi AA; Santini D; Tucci M; De Giorgi U; Bossi P; Ibrahim T; Cavanna L; Lanzetta G; Rossi M; Rossetti G; Airoldi M; Comandone A; Cinieri S
Support Care Cancer; 2024 Mar; 32(3):202. PubMed ID: 38427111
[TBL] [Abstract][Full Text] [Related]
11. Use of denosumab in castration sensitive prostate cancer.
Laurent MR
BMJ; 2023 Dec; 383():2827. PubMed ID: 38049158
[No Abstract] [Full Text] [Related]
12. Denosumab: a new option in the treatment of bone metastases from urological cancers.
Yuasa T; Yamamoto S; Urakami S; Fukui I; Yonese J
Onco Targets Ther; 2012; 5():221-9. PubMed ID: 23055747
[TBL] [Abstract][Full Text] [Related]
13. Denosumab for treatment of hypercalcemia of malignancy.
Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases.
Yonemori K; Fujiwara Y; Minami H; Kitagawa K; Fujii H; Arai T; Sohn W; Ohkura M; Ohtsu T
Cancer Sci; 2008 Jun; 99(6):1237-42. PubMed ID: 18429961
[TBL] [Abstract][Full Text] [Related]
15. Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis.
Wei J; Wang Z; Makarov D; Li X
Am J Clin Exp Urol; 2013; 1(1):30-8. PubMed ID: 25374898
[TBL] [Abstract][Full Text] [Related]
16. Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer.
Chang H; Marquez J; Chen BK; Kim DM; Cheng ML; Liu EV; Yang H; Zhang L; Sinha M; Cheung A; Kwek SS; Chow ED; Bridge M; Aggarwal RR; Friedlander TW; Small EJ; Anderson M; Fong L
Cancer Immunol Res; 2024 Apr; 12(4):453-461. PubMed ID: 38276989
[TBL] [Abstract][Full Text] [Related]
17. Denosumab: A bone antiresorptive drug.
Dahiya N; Khadka A; Sharma AK; Gupta AK; Singh N; Brashier DB
Med J Armed Forces India; 2015 Jan; 71(1):71-5. PubMed ID: 25609868
[TBL] [Abstract][Full Text] [Related]
18. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.
Aapro M; Saad F
Ther Adv Urol; 2012 Apr; 4(2):85-101. PubMed ID: 22496711
[TBL] [Abstract][Full Text] [Related]
19. Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?
von Moos R; Haynes I
J Clin Med; 2013 Aug; 2(3):89-102. PubMed ID: 26237064
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid in the management of metastatic bone disease.
Polascik TJ; Mouraviev V
Ther Clin Risk Manag; 2008 Feb; 4(1):261-8. PubMed ID: 18728715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
